n-6:n-3 PUFA ratio is involved in regulating lipid metabolism and inflammation in pigs

Br J Nutr. 2014 Feb;111(3):445-51. doi: 10.1017/S0007114513002584. Epub 2013 Aug 15.

Abstract

The objective of the present study was to investigate the optimal dietary n-6:n-3 PUFA ratios that regulate lipid metabolism and inflammation in pigs. A total of ninety-six cross-bred (Large White × Landrace) growing-finishing pigs (73·8 (SEM 1·6) kg) were chosen and fed one of the four isoenergetic diets with n-6:n-3 PUFA ratios of 1:1, 2·5:1, 5:1 and 10:1. The growth performance of pigs fed the diet with an n-6:n-3 PUFA ratio of 5:1 was the best, but the group fed the diet with an n-6:n-3 PUFA ratio of 1:1 had the highest muscle mass and the lowest adipose tissue mass (P< 0·05). The concentrations of IL-6 and IL-1β of pigs fed the diet with an n-6:n-3 PUFA ratio of 1:1 were decreased compared with those of the other groups (P< 0·05). The concentration of adiponectin of pigs fed the diet with an n-6:n-3 PUFA ratio of 1:1 was also markedly decreased, but the concentration of leptin was increased compared with that of the groups fed the diets with n-6:n-3 PUFA ratios of 5:1 and 10:1 (P< 0·05). Additionally, the optimal dietary ratios of n-6:n-3 PUFA of 1:1 and 5:1 markedly suppressed the expression levels of lipid metabolism-related genes and proteins such as phosphoinositide-3-kinase-α, fatty acid transport protein-1 and PPARγ. They also significantly suppressed the expression levels of the inflammatory cytokines IL-1β, TNF-α and IL-6. The results indicated that the optimal n-6:n-3 PUFA ratios of 1:1 and 5:1 exerted beneficial effects on lipid metabolism and inflammatory system, leading to the availability of more energy and nutrients for high performance and homeostatic pathways.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipokines / agonists
  • Adipokines / antagonists & inhibitors
  • Adipokines / blood
  • Adipokines / metabolism
  • Adiposity
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / metabolism*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • China
  • Crosses, Genetic
  • Cytokines / agonists
  • Cytokines / antagonists & inhibitors
  • Cytokines / blood
  • Cytokines / metabolism
  • Dietary Fats / adverse effects
  • Dietary Fats / metabolism*
  • Dietary Fats / therapeutic use
  • Energy Intake
  • Fatty Acids, Omega-3 / adverse effects
  • Fatty Acids, Omega-3 / metabolism*
  • Fatty Acids, Omega-3 / therapeutic use
  • Fatty Acids, Omega-6 / adverse effects
  • Fatty Acids, Omega-6 / metabolism*
  • Fatty Acids, Omega-6 / therapeutic use
  • Gene Expression Regulation, Developmental
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / metabolism
  • Hypolipidemic Agents / therapeutic use
  • Lipid Metabolism*
  • Male
  • Muscle Development
  • Muscle, Skeletal / growth & development
  • Muscle, Skeletal / immunology
  • Muscle, Skeletal / metabolism*
  • Random Allocation
  • Subcutaneous Fat, Abdominal / growth & development
  • Subcutaneous Fat, Abdominal / immunology
  • Subcutaneous Fat, Abdominal / metabolism*
  • Sus scrofa
  • Weight Gain

Substances

  • Adipokines
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cytokines
  • Dietary Fats
  • Fatty Acids, Omega-3
  • Fatty Acids, Omega-6
  • Hypolipidemic Agents